Welcome to our dedicated page for XWELL news (Ticker: XWEL), a resource for investors and traders seeking the latest updates and insights on XWELL stock.
XWELL Inc. (Nasdaq: XWEL) operates at the intersection of travel wellness and biosecurity, offering premium spa services and health solutions through brands like XpresSpa® and XpresTest®. This page serves as the definitive source for official company announcements and market-moving developments.
Investors and industry observers will find curated press releases covering operational milestones, including airport spa expansions, biosecurity partnerships, and service innovations. Our repository ensures timely access to earnings reports, leadership updates, and strategic initiatives shaping this health and wellness leader.
All content undergoes strict verification to maintain accuracy and compliance with financial disclosure standards. For ongoing monitoring of XWELL's progress in redefining travel health experiences, bookmark this page and check regularly for updates.
XWELL, Inc. (Nasdaq: XWEL) has announced a registered direct offering of 652,705 shares of common stock at $2.18 per share, priced at a premium to market. The offering is expected to close around August 8, 2024, generating gross proceeds of approximately $1.4 million. XWELL plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement on Form S-3. A final prospectus supplement and accompanying base prospectus will be filed with the SEC, available at www.sec.gov.
XWELL (Nasdaq: XWEL) has announced that the director candidate nomination notice submitted by CPC Pain & Wellness SPV, (CPC) is invalid. CPC, a recently formed special purpose vehicle, acquired a 9.42% stake in XWELL last month. XWELL claims CPC's Schedule 13D filing is deficient, lacking details about its plans for the company.
XWELL suspects CPC aims to gain board control to engineer a transaction with an underperforming affiliate, potentially resulting in a 'Take-Under' deal that could undervalue the company and dilute stockholders. The company calls on CPC to update its Schedule 13D with transparent information about its plans and recent litigation. XWELL advises stockholders to be cautious of communications from CPC but states no immediate action is required.
XWELL has announced the grand opening of a new XpresSpa location at Philadelphia International Airport (PHL), a major travel hub with over 28 million passengers annually. The new spa, located in Terminal B near Gate B2, features innovative autonomous and semi-autonomous services such as robotic manicures, therapeutic thermal massages, and automated massage options. This expansion is part of XWELL's strategy to grow its footprint in the Northeast corridor and drive revenue growth through labor-lite and tech-forward solutions. Additionally, the new location offers a diverse retail selection tailored for travelers. Later this summer, XpresSpa will also launch a new retail location at Penn Station in New York City.
XWELL introduces new esthetic facial services at its Naples Wax Center flagship in Naples, FL, expanding its service offerings with advanced treatments. The new services include the Microderm Infusion Facial, LightStim Invigorating Light Facial, and Classic Refreshing Facial. These treatments aim to enhance skincare by utilizing innovative technologies like DiamondGlow and LED light therapy. XWELL's CEO, Scott Milford, emphasizes the goal to exceed customer expectations and boost revenue through these high-margin services. Additionally, curated retail products from SkinMedica and PCA Skin will be available. This initiative aligns with XWELL’s strategy to grow its out-of-airport portfolio and tech-forward initiatives.
XWELL announced the introduction of the Ceragem V6 Therapeutic Thermal Massager at select XpresSpa locations starting in Q2 2024. This FDA-cleared Class II medical device aims to enhance blood circulation, relieve muscle and joint discomfort, and offer muscle relaxation. The new service will be first launched at Salt Lake City International Airport on May 22, 2024, with subsequent launches at Philadelphia and Orlando airports. XWELL's CEO, Scott Milford, states that this integration supports their strategy to increase revenue and retail traffic cost-effectively. The partnership with Ceragem International is part of XWELL's broader tech-forward initiatives, including IV hydration drip therapies and robotic manicures, solidifying its position in travel wellness.
XWELL, an authority in wellness solutions, reported its first quarter 2024 financial results. The company saw a 24% revenue growth to $8.7 million compared to the same quarter in 2023. Total cost of sales decreased by 7%, and general and administrative expenses were cut by 47%, leading to a 62% reduction in operating loss, now at $2.4 million. XWELL continued to enhance its business model by expanding its CDC Traveler-based Genomic Surveillance Program to Miami and Chicago airports.
Additionally, the company signed leases for new Naples Wax Center locations in Florida and confirmed the opening of an XpresSpa at Penn Station in New York. XWELL also introduced new tech-forward wellness services at its airport locations, including IV hydration therapy. Overall, XWELL aims to return to profitability by focusing on strategic priorities and expanding its wellness portfolio.
XWELL, Inc. (Nasdaq: XWEL) introduces IV hydration drip therapy at its Miami International Airport location in partnership with Revitalize IV Lounge. The therapy aims to deliver essential nutrients directly into the bloodstream, boosting energy levels and aiding recovery from jet lag and illness. The service offers four options starting at $220 per session, with potential for revenue growth and expansion to other markets.
FAQ
What is the current stock price of XWELL (XWEL)?
What is the market cap of XWELL (XWEL)?
